Matinas BioPharma Holdings, Inc. MTNB
Nov 4, 2026, 1:43 PM EST
- YTD
- +97.95%
- 1 year
- -8.66%
- Market cap
- 1.14M
- EPS (ttm)
- -17.55
- Shares out
- 5.09M
- Forward P/E
- -0.17
- YTD return
- +97.95%
- 1-year return
- -8.66%
- Volume
- 15.60K
- Avg volume
- 94.28K
- Open
- 1.17
- Previous close
- 1.14
- Day's range
- 1.07 – 1.19
- 52-week range
- 0.966 – 19.95
- Beta
- 1.73
5D -0.65 (-36.31%)
Key statistics
- Enterprise value
- -7.89M
- PEG ratio
- 0.00
- Price / book
- 0.12
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -9.13M
- Total cash
- 14.31M
- Total debt
- 3.24M
- Return on equity
- -97.59%
- Short % of float
- 0.66%
- 50-day average
- 1.38
- 200-day average
- 6.37
Analyst view
- Strong buy0
- Buy0
- Hold2
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.78.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -0.85 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -1.00 | — | — |
| May 9, 2024 | Mar 1, 2024 | 0.00 | -1.50 | — | — |
| Mar 27, 2024 | Dec 1, 2023 | 0.00 | -1.50 | — | — |
| Nov 8, 2023 | Sep 1, 2023 | 0.00 | -1.50 | — | — |
| Aug 9, 2023 | Jun 1, 2023 | 0.00 | -1.50 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 31, 2024 | Maxim Group | down | Buy | Hold |
| Jan 31, 2023 | HC Wainwright & Co. | reit | — | Buy |
| Aug 13, 2020 | Aegis Capital | main | — | Buy |
| Jan 27, 2020 | Piper Sandler | init | — | Overweight |
| Jan 24, 2020 | SunTrust Robinson Humphrey | init | — | Buy |
| Jun 26, 2019 | HC Wainwright & Co. | init | — | Buy |
About Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It also offers MAT2501, an orally administered formulation of amikacin to treat chronic and acute bacterial infections, as well as non-tuberculosis mycobacterium. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases for the development of oral formulations of Gilead's remdesivir; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- matinasbiopharma.com
News
Matinas Biopharma Terminates Agreement With Former Financial Advisor On Nov 3, 2026 
12 Health Care Stocks Moving In Tuesday's After-Market Session 
12 Health Care Stocks Moving In Friday's After-Market Session 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
12 Health Care Stocks Moving In Monday's Intraday Session - 12 Health Care Stocks Moving In Monday's Pre-Market Session
- 12 Health Care Stocks Moving In Monday's After-Market Session
Matinas BioPharma Board Approves 1-For-15 Reverse Stock Split Effective September 28, 2026 
GH Power Signs Multi-Year Hydrogen Offtake Agreement with Change Energy for Hamilton Facility Output 
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
Your note
Sign in to keep a note on MTNB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CONRAD HERBERT J | Director | Stock Gift | Jun 21, 2022 | 0 |
| ENDE ERIC J | Director | Conversion of Exercise of derivative security | Jun 17, 2021 | 144,092 |
| JABBOUR JEROME D | Chief Executive Officer | Conversion of Exercise of derivative security | Jun 17, 2021 | 840,011 |
| KUCINSKI KEITH A | Chief Financial Officer | Purchase | Nov 24, 2019 | 94,500 |
| LEPORE PATRICK G | Director | Purchase | May 13, 2020 | 400,000 |
| MANNINO RAPHAEL J | Officer | Conversion of Exercise of derivative security | Jun 17, 2021 | 1,457,560 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| JTC Employer Solutions Trusteee Ltd | 15.23% | 775,000 | 403.08K | Sep 29, 2024 |
| Vanguard Group Inc | 3.66% | 186,357 | 96.92K | Sep 29, 2024 |
| Highbridge Capital Management, LLC. | 2.54% | 128,956 | 67.07K | Sep 29, 2024 |
| Sargent Investment Group, LLC | 1.58% | 80,240 | 41.73K | Sep 29, 2024 |
| Blackrock Inc. | 0.98% | 49,650 | 25.82K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.92% | 46,729 | 24.30K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.37% | 120,412 | 62.63K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.15% | 58,387 | 30.37K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.55% | 28,018 | 14.57K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.15% | 7,652 | 3.98K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.12% | 6,298 | 3.27K | Oct 30, 2024 |
| Vanguard Balanced Index Fund | 0.06% | 3,296 | 1.71K | Sep 29, 2024 |